Abstract：Objective To observe the clinical effect of Duloxetine in treating Parkinson disease fatigue. Methods From July 2020 to March 2022, 58 patients with Parkinson disease fatigue who were treated and followed up in the Department of Neurology of the First Hospital of Zhangjiakou they were divided into intervention group 1 and intervention group 2 by random number table method, with 29 patients in each group. Intervention group 1 was treated with parkinson’s drugs, and intervention group 2 was treated with Duloxetine on this basis. Fatigue scores, depression scores and serum levels of 5-hydroxytryptamine (5-HT) and norepinephrine (NE) before and after treatment were compared between the two groups. Results The overall analysis showed that there were significant differences between groups, time point comparison and interaction (P＜0.05). Intra-group comparison: the FS-14 score and depression score between the two groups at each time point and the differences were statistically significant (P＜0.05). Inter-group comparison: the FS-14 score and depression score of intervention group 2 were lower than those of intervention group 1 at each time point after treatment, and the differences were statistically significant (P＜0.05). The fatigue control effect of intervention group 2 was better than that of intervention group 1, the difference was statistically significant (P＜0.05). Intra-group comparison: the 5-HT and NE levels between the two groups at each time point and the differences were statistically significant (P＜0.05). Inter-group comparison: After treatment, the levels of 5-HT and NE in intervention group 2 were higher than those in intervention group 1 at each time point, and the differences were statistically significant (P＜0.05). Conclusion On the basis of optimizing Parkinson’s drug, Duloxetine can improve fatigue control effect by regulating serum 5-HT and NE levels, and its effect on fatigue improvement is not dependent on improving depressive symptoms.
京公网安备 11010502046598号